Onco Actu du 25 mars 2019

	1. BIOLOGIE
Immune Sculpting of Cancer Evolution [Ecology & Evolution] Just as evolution held the key to understanding targeted therapy resistance, it is increasingly likely that viewing cancer through an evolutionary lens will provide further insight into how escape ensues from a predatory immune environment.
	2.11 ETIOLOGIE - ALIMENTATION
Revealed: no need to add cancer-risk nitrites to ham [The Guardian] A bombshell internal report written for the British meat industry reveals nitrites do not protect against botulism – the chief reason ham and bacon manufacturers say they use the chemicals.
	2.6 ETIOLOGIE - ENVIRONNEMENT
Pesticide use and risk of non-Hodgkin lymphoid malignancies in agricultural cohorts from France, Norway and the USA: a pooled analysis from the AGRICOH consortium [International Journal of Epidemiology] We did not observe an association between risk of NHL overall and ever use of glyphosate, a broad-spectrum herbicide used in agriculture and other settings.
	3. PRÉVENTION
Topical immunotherapy keeps skin cancer risk at bay [WUSTL] A combination of two topical creams already shown to clear precancerous skin lesions from sun-damaged skin also lowers the risk that patients will later develop squamous cell carcinoma of the skin.
	4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
Hacking into macrophage attack circuits, Stanford scientists pitch a better early-warning alert system for tumors [EndPoints] Pioneering a new definition of the concept “immunodiagnotics,” Sanjiv “Sam” Gambhir of Stanford’s Canary Center for Early Detection repurposed macrophages to report the presence of disease or damaged cells, achieving detection of tumors as small as 4 millimeters in diameter, outperforming “some of the most advanced early tumor detection methods out there.”
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
Are genetic tests useful to predict cancer? [The Guardian] The health secretary’s call for tests to be rolled out on NHS was met with controversy.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Nature’s Bounty: Revitalizing the Discovery of New Cancer Drugs from Natural Products [NCI] Dr. Grkovic has spent the last several years intimately involved in improving processes for analyzing products of nature—from marine creatures to soil-dwelling fungi to plant leaves—to see whether chemical compounds within them might be starting blocks for new cancer drugs.
Three-pronged attack can overcome drug resistance in bowel cancer [Institute of Cancer Research] When they exposed cells for several weeks to a triple combination of cobimetinib, pictilisib and a third drug called navitoclax which inhibits molecules in the BCL-2 family, the emergence of resistance was completely blocked.
	5.10 TRAITEMENTS - ESSAIS
Long-term data shows promise in breast cancer biosimilar [Pharma Times] The a three-year follow-up study comparing biosimilar Ontruzant (trastuzumab) to a reference version - Herceptin - has found that the drug shows comparable overall survival and cardiac safety in early or locally advanced HER2-positive breast cancer.
	5.2 PHARMA
GSK’s anti-BCMA multiple myeloma drug shows durability in updated data [Fierce Biotech] GSK's news comes shortly after AbbVie and Teneobio inked a $90 million pact to develop a BCMA- and CD3-targeting bispecific antibody for multiple myeloma.
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma [Genmab] The submission is based on data from the Phase III MAIA study of daratumumab in combination with Rd as treatment for patients with newly diagnosed multiple myeloma, who are not candidates for high dose chemotherapy and ASCT.
	5.2.3 PHARMA - ÉCONOMIE
Turning Point Therapeutics eyes $100M IPO to propel treatment for drug-resistant tumors [Fierce Biotech] The drug is in phase 1 for ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive advanced solid tumors in patients who have been previously treated with tyrosine kinase inhibitors and those who have not.
Turning Point Therapeutics Plans IPO to Advance Targeted Cancer Drugs [Xconomy] The San Diego biotech is developing what it describes as a “next-generation” drug as a treatment for cancers associated with genetic variations that alter the enzymes ALK, ROS1, and TRK.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
EMA Management Board: highlights of March 2019 meeting [EMA] Despite the proactive approach by the European medicines regulatory network, there is still a high risk of supply issues with some medicines if the UK were to leave the EU without a withdrawal agreement.
	5.4 TRAITEMENTS - ECONOMIE
Targeted lymphoma drug gets green light for NHS in England [Cancer Research UK] NICE had initially rejected the targeted treatment (brentuximab vedotin) because it couldn’t calculate how much the treatment would cost. But the company has since submitted further evidence, which helped NICE clarify how much the drug is likely to cost the NHS.
	5.9 AACR
Fred Hutch at AACR: NextGen star, liquid biopsies, immunotherapy, cancer genetics, health disparities and more [Fred Hutch] Fred Hutchinson Cancer Research Center’s latest findings in immunotherapies, nanoparticles to deliver gene therapy, the genetic underpinnings of cancer, insights on health disparities and more will be showcased at the annual meeting of the American Association for Cancer Research.
	6.7 DMP, BIG DATA & APPLIS
Evolving Challenges And Directions In Data Commons: Updates From Bio-IT World West [Bio-IT World] Grossman then introduced the Data Commons Framework Services (DCFS), a set of software services for building and operating data commons and cloud-based resources, which can also support multiple data commons, knowledgebases, and applications as part of a data ecosystem.
	6.7.2 APPLIS
Your health app could be sharing your medical data [Reuters] Grundy’s team tested 24 top-rated publicly available medication apps designed to work on Android phones in the UK, the U.S., Canada and Australia. The interactive apps provided information about medication dispensing, administration or use.